Paid Clinical Trials in Connecticut

Connecticut has 1,295 paid clinical trials enrolling now across cities including New Haven, Hartford and Stamford. Search by condition, age, or phase to find compensated research studies accepting participants near you.

Both patients and healthy volunteers may qualify. Most studies offer compensation for time and travel.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: September 11, 2026.

Filter results

State

City

Recruitment status

Phase

Study type

Intervention

Condition

Sex

Age

Healthy volunteers only

1,144 clinical trials

Get a weekly email when new trials open in New Haven, CT.

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

for Obesity With Diabetes

Sites in Stamford +58 more locations

Sponsor: Kailera

Sex: All·Age: 18+

Code: NCT07284901·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

for Obesity

Drug: Semaglutide

Sites in Stamford, Hamden +25 more locations

Sponsor: Kailera

Sex: All·Age: 18+

Code: NCT07284979·Phase 3·Recruiting·Listed Dec 2025

Apply to this trial

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

for Ovarian Neoplasms

Sites in Farmington +86 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07213804·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

for Breast Neoplasms

Sites in New Haven, Hartford +47 more locations

Sponsor: Natera, Inc.

Sex: All·Age: 18+

Code: NCT07214532·Recruiting·Listed Oct 2025

Apply to this trial

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

for Metabolic Dysfunction Associated Steatohepatitis (MASH)

Drug: Survodutide

Sites in New Haven, Bristol +161 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632444·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

Sites in Stamford +120 more locations

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis

for Transthyretin Amyloid Cardiomyopathy (ATTR CM)

Drug: Coramitug

Sites in New Haven +60 more locations

Sponsor: Novo Nordisk A/S

Sex: All·Age: 18+

Code: NCT07207811·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

for Melanoma

Sites in New Haven +90 more locations

Sponsor: Regeneron Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06246916·Phase 3·Recruiting·Listed Feb 2024

Apply to this trial

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

for Metabolic Dysfunction Associated Steatohepatitis

Drug: Survodutide

Sites in Bristol +125 more locations

Sponsor: Boehringer Ingelheim

Sex: All·Age: 18+

Code: NCT06632457·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

for Breast Cancer

Sites in New Haven +171 more locations

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06492616·Phase 3·Recruiting·Listed Jul 2024

Apply to this trial

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

for Proteinuric Kidney Disease

Sites in New Haven, Bloomfield +137 more locations

Sponsor: Vertex Pharmaceuticals Incorporated

Sex: All·Age: 10 - 65

Code: NCT05312879·Phase 2, Phase 3·Recruiting·Listed Apr 2022

Apply to this trial

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

for Carcinoma, Non-Small-Cell Lung

Drug: Amivantamab

Sites in New Haven +124 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06667076·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

for Endometrial Cancer

Sites in Hartford, Norwalk +66 more locations

Sponsor: Genmab

Sex: Female·Age: 18+

Code: NCT07166094·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

for Colitis, Ulcerative

Sites in Hartford +49 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 12+

Code: NCT07196748·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

for Patients With Non-Small Cell Lung Cancer

Drug: OSE2101

Sites in Norwich +33 more locations

Sponsor: OSE Immunotherapeutics

Sex: All·Age: 18+

Code: NCT06472245·Phase 3·Recruiting·Listed Jun 2024

Apply to this trial

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

for Renal Cell Carcinoma (RCC)

Sites in New Haven +43 more locations

Sponsor: Exelixis

Sex: All·Age: 18+

Code: NCT05176483·Phase 1·Recruiting·Listed Jan 2022

Apply to this trial

A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)

for Metastatic Castration-resistant Prostatic Neoplasms

Drug: Pasritamig

Sites in Hartford +51 more locations

Sponsor: Janssen Research & Development, LLC

Sex: Male·Age: 18+

Code: NCT07164443·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

for Pediatric Migraine

Sites in Stamford, Cromwell +76 more locations

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT04649242·Phase 3·Recruiting·Listed Dec 2020

Apply to this trial

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

for Geographic Atrophy Secondary to Age-related Macular Degeneration

Drug: Pegcetacoplan

Sites in Danbury +77 more locations

Sponsor: Apellis Pharmaceuticals, Inc.

Sex: All·Age: 60+

Code: NCT07215390·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

for Osteoarthritis

Drug: Orforglipron

Sites in Waterbury +25 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT07153471·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

for End Stage Kidney Disease

Drug: Clazakizumab

Sites in Middlebury, Bloomfield +146 more locations

Sponsor: CSL Behring

Sex: All·Age: 18+

Code: NCT05485961·Phase 2, Phase 3·Recruiting·Listed Aug 2022

Apply to this trial

A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease

for Alzheimers Disease

Drug: Trontinemab

Sites in New Haven +32 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 90

Code: NCT07170150·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

for Triple-Negative Breast Cancer

Sites in New Haven, Farmington +81 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06393374·Phase 3·Recruiting·Listed May 2024

Apply to this trial

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

for Migraine

Drug: Ubrogepant

Sites in Stamford +86 more locations

Sponsor: AbbVie

Sex: All·Age: 6 - 17

Code: NCT05125302·Phase 3·Recruiting·Listed Nov 2021

Apply to this trial

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in Hartford +90 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06890598·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

for Carcinoma, Non-Small-Cell Lung

Drug: LY3537982

Sites in New Haven +87 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT06119581·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

for Colorectal Neoplasms

Drug: Amivantamab

Sites in New Haven +80 more locations

Sponsor: Janssen Research & Development, LLC

Sex: All·Age: 18+

Code: NCT06662786·Phase 3·Recruiting·Listed Oct 2024

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

for Crohn's Disease

Drug: Tulisokibart

Sites in New Haven +70 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 16 - 80

Code: NCT06430801·Phase 3·Recruiting·Listed May 2024

Apply to this trial

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

for Obesity

Sites in Stamford +42 more locations

Sponsor: Eli Lilly and Company

Sex: All·Age: 18 - 75

Code: NCT06143956·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

for Parkinson's Disease

Drug: Prasinezumab

Sites in New Haven +52 more locations

Sponsor: Hoffmann-La Roche

Sex: All·Age: 50 - 85

Code: NCT07174310·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

for Geographic Atrophy (GA)

Sites in Waterford +55 more locations

Sponsor: ONL Therapeutics

Sex: All·Age: 55+

Code: NCT06659445·Phase 2·Recruiting·Listed Oct 2024

Apply to this trial

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

for Advanced Non-Small Cell Lung Cancer

Drug: Adagrasib

Sites in Norwich +191 more locations

Sponsor: Mirati Therapeutics Inc.

Sex: All·Age: 18+

Code: NCT04613596·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine

for Acute Treatment of Migraine

Drug: Rimegepant

Sites in Stamford, Cromwell +59 more locations

Sponsor: Pfizer

Sex: All·Age: 6 - 17

Code: NCT04743141·Phase 3·Recruiting·Listed Feb 2021

Apply to this trial

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

for Neoplasms

Sites in New Haven +76 more locations

Sponsor: Celgene

Sex: All·Age: All ages

Code: NCT03435796·Phase 2, Phase 3·Recruiting·Listed Feb 2018

Apply to this trial

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

for Bipolar I or II Disorder

Sites in Cromwell +45 more locations

Sponsor: AbbVie

Sex: All·Age: 18 - 65

Code: NCT07220460·Phase 2·Recruiting·Listed Oct 2025

Apply to this trial

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

for Chronic Spontaneous Urticaria (CSU)

Drug: Remibrutinib

Sites in Farmington +128 more locations

Sponsor: Novartis Pharmaceuticals

Sex: All·Age: 18+

Code: NCT06868212·Phase 3·Recruiting·Listed Mar 2025

Apply to this trial

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

for Metastatic Colorectal Cancer (CRC)

Drug: Bevacizumab

Sites in New Haven, Hartford +100 more locations

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT07228832·Phase 3·Recruiting·Listed Nov 2025

Apply to this trial

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

for Bipolar Disorder Type I With Mania

Drug: KarXT

Sites in New Haven +45 more locations

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18 - 65

Code: NCT06929273·Phase 3·Recruiting·Listed Apr 2025

Apply to this trial

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Sites in New Haven +54 more locations

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 18+

Code: NCT06136650·Phase 3·Recruiting·Listed Nov 2023

Apply to this trial

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

for PIK3CA Mutation

Sites in New Haven +51 more locations

Sponsor: Relay Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06982521·Phase 3·Recruiting·Listed May 2025

Apply to this trial